Enovix price target lowered to $21 from $22 at Canaccord

Summary of Key Points Core Viewpoint - Canaccord analyst George Gianarikas has reduced the price target for Enovix (ENVX) from $22 to $21 while maintaining a Buy rating on the shares, indicating a continued positive outlook despite recent delays in anticipated financial performance [1]. Company Analysis - The recent quarter has introduced another delay in the expected "hockey stick" profit and loss (P&L) trajectory that investors have been anticipating, suggesting that the company may face ongoing challenges in achieving its financial goals [1]. - Investors are advised to remain patient as the company navigates these delays, indicating a long-term investment perspective despite short-term setbacks [1].